Biomea Fusion Doses First Patient In Phase I/Ib Clinical Trial Of BMF-219 In KRAS Mutant Solid Tumors
Biomea Fusion Doses First Patient In Phase I/Ib Clinical Trial Of BMF-219 In KRAS Mutant Solid Tumors
生物融合劑量第一患者在KRAS 突變實體瘤中 BMF-219 的 I/IB 期臨床試驗
- BMF-219 is the first menin inhibitor to be clinically studied in patients with KRAS-mutated non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC)
- A pan-KRAS inhibitor targeting multiple KRAS mutations (including G12C, G12D and G12R, among others) has the potential to treat 25-35% of NSCLC patients, 35-45% of CRC patients, and approximately 90% of PDAC patients
- BMF-219 is now in clinical development across eight liquid and solid tumor types, as well as for patients with type 2 diabetes
- BMF-219 是第一個臨床研究的半乳素抑制劑，用於患有 KRS 突變的非小細胞肺癌（NSCLC），結直腸癌（CRC）和胰腺導管腺癌（PDAC）患者
- 一種靶向多種 KRAS 突變的泛克拉斯抑制劑（包括 G12C、G12D 和 G12R 等）有可能治療 25-35% 的非小細胞肺癌患者、35-45% 的 CRC 患者，以及約 90% 的 PDAC 患者
- BMF-219 目前正在臨床開發，涵蓋八種液體和實體腫瘤類型，以及 2 型糖尿病患者